← Leaderboards
Mauricio De Aguiar Martins
University Of Florida
$18,939,893
Attributed
$21,259,101
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,259,101 · 9
By mechanism
R01$13,312,548 · 4
U19$4,302,151 · 1
U01$1,257,182 · 1
K01$992,805 · 1
R56$917,294 · 1
R21$477,121 · 1
Top collaborators
- David T Curiel2 shared
- Michael R. Farzan2 shared
- Michael David Alpert1 shared
- Brian D Quinlan1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Stephanie Karst$15,010,959
- Olivia A Bailey$117,681
- Amy Yomiko Vittor$2,166,391
- Christina Lynn Graves$38,750
- Dorina Avram$13,642,871
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesInfectionMacaca MulattaMediatingDependovirusSerumVirusPreventDoseCellsSimian Human Immunodeficiency VirusHiv InfectionsImmunityAntiretroviral TherapyAnimalsExperimental StudySafetyMonkeysReceptorPropertyVirus ReplicationVectorImmunoglobulin GIn Vivo
Grant awards (31)
Vectored HIV Immunotherapy via in vivo B cell editing$1,272,001
R01 · FY2025 · AI
Leveraging prenatal tolerance to improve AAV/bNAb therapy outcomes in infancy$1,257,182
U01 · FY2025 · AI · contact PI
Non-viral gene therapy with eCD4-Ig$917,294
R56 · FY2025 · AI
Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies$835,249
R01 · FY2025 · AI · contact PI
Project 1: Establishing a robust functional cure$1,698,874
U19 · FY2024 · AI · contact PI
Vectored HIV Immunotherapy via in vivo B cell editing$1,289,517
R01 · FY2024 · AI
Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies$861,082
R01 · FY2024 · AI · contact PI
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection$812,183
R01 · FY2024 · HD · contact PI
eCD4-Ig for preventing and treating obstetric HIV infection$803,760
R01 · FY2024 · HD · contact PI
Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies$896,461
R01 · FY2023 · AI · contact PI
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection$825,106
R01 · FY2023 · HD · contact PI
eCD4-Ig for preventing and treating obstetric HIV infection$797,205
R01 · FY2023 · HD · contact PI
Project 1: Establishing a robust functional cure$606,803
U19 · FY2023 · AI · contact PI
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection$818,853
R01 · FY2022 · HD · contact PI
eCD4-Ig for preventing and treating obstetric HIV infection$795,033
R01 · FY2022 · HD · contact PI
Project 1: Establishing a robust functional cure$508,718
U19 · FY2022 · AI · contact PI
A nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women$180,415
R21 · FY2022 · AI · contact PI
A nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women$24,080
R21 · FY2022 · AI · contact PI
Project 1: Establishing a robust functional cure$1,025,256
U19 · FY2021 · AI · contact PI
eCD4-Ig for preventing and treating obstetric HIV infection$603,762
R01 · FY2021 · HD · contact PI
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection$470,736
R01 · FY2021 · HD · contact PI
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection$353,525
R01 · FY2021 · HD · contact PI
A nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women$272,626
R21 · FY2021 · AI · contact PI
eCD4-Ig for preventing and treating obstetric HIV infection$197,968
R01 · FY2021 · HD · contact PI
eCD4-Ig for preventing and treating obstetric HIV infection$844,588
R01 · FY2020 · HD · contact PI
AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection$835,519
R01 · FY2020 · HD · contact PI
Project 1: Establishing a robust functional cure$462,500
U19 · FY2020 · AI · contact PI
Ipilimumab as an adjuvant for HIV vaccines$200,007
K01 · FY2018 · OD · contact PI
Ipilimumab as an adjuvant for HIV vaccines$122,755
K01 · FY2018 · OD · contact PI
Ipilimumab as an adjuvant for HIV vaccines$329,243
K01 · FY2017 · OD · contact PI
Ipilimumab as an adjuvant for HIV vaccines$340,800
K01 · FY2016 · OD · contact PI